Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair
Focus will be on modest, early-stage deals as the pharma seeks next blockbuster
As Ken Frazier’s successor as CEO, Robert Davis will need to deliver a pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff.
Feb 5, 2021 | 2:30 AM GMT
As Merck’s Robert Davis prepares to take the helm as CEO, his primary challenge will be executing on a pipeline robust enough to carry the